Az orális levodopakezelés jellegzetességei előrehaladott Parkinson-kórban a marosvásárhelyi neurológiai klinikák tapasztalatában
| العنوان: | Az orális levodopakezelés jellegzetességei előrehaladott Parkinson-kórban a marosvásárhelyi neurológiai klinikák tapasztalatában |
|---|---|
| المؤلفون: | Attila Rácz, József Attila Szász, Károly Orbán-Kis, Viorelia Adelina Constantin, Tamás Vajda, Szabolcs Szatmári, István Mihály, Lajos Csaba Domokos |
| المصدر: | Orvosi Hetilap. 160:662-669 |
| بيانات النشر: | Akademiai Kiado Zrt., 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Pediatrics, medicine.medical_specialty, Levodopa, Neurology, Parkinson's disease, business.industry, Retrospective cohort study, General Medicine, Disease, medicine.disease, nervous system diseases, 03 medical and health sciences, 0302 clinical medicine, Quality of life, Dyskinesia, medicine, 030211 gastroenterology & hepatology, Dosing, medicine.symptom, business, medicine.drug |
| الوصف: | Abstract: Introduction: The motor and non-motor complications of Parkinson’s disease impair the patients’ quality of life and limit therapeutical options. There are no clear criteria for ‘advanced’ Parkinson’s disease or for the optimal moment for invasive therapies. There is little evidence regarding the upper limits of levodopa doses, and how these may be influenced by the availability of device-aided therapies. Aim: To analyze substitution therapy in patients with advanced Parkinson’s disease. Method: In our retrospective study, we analyzed the data from all patients with advanced Parkinson’s disease hospitalized between 1st June 2011 and 31st May 2017, receiving combined levodopa treatment at least 4×/day, reporting a minimum of 2 hours off periods, with or without dyskinesia. We analyzed levodopa therapy for patients who were recommended either device-aided or conservative therapy. Results: Out of 311 patients with advanced Parkinson’s disease, for 125 we proposed device-aided therapies whereas in 42 patients we increased the levodopa dose. The average levodopa doses and the administration rate were higher for the 107 patients tested for levodopa-carbidopa intestinal gel. Disease duration, mean levodopa doses and frequency of dosing were all higher in patients proposed for device-aided therapies versus patients with continued conservative treatment. Conclusion: Our patients were on lower levodopa doses (compared to literature), but the combinations were used more often. Device-aided therapies should be considered in patients with severe motor complications who receive at least 750–1000 mg levodopa daily, divided minimum 5×/day. These patients need to be tested in specialized centers by multidisciplinary teams in order to make the best decision for further action. Orv Hetil. 2019; 160(17): 662–669. |
| تدمد: | 1788-6120 0030-6002 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::eb6c47235fa10a5301cbb5c390e256e3 https://doi.org/10.1556/650.2019.31354 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi...........eb6c47235fa10a5301cbb5c390e256e3 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17886120 00306002 |
|---|